ArticleMolecules (Basel, Switzerland)2021
Selected Thoughts on Hydrophobicity in Drug Design.
Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Short-Chain Oleanolic Acid Esters and Furoyl Hybrids: Pharmacological Prediction, ADMETox Profiling, In Vitro Cytotoxicity Evaluation, Antioxidant Testing and EGFR Docking.Pharmaceutics · 2026Article
- Quinuclidin-3-one-based quaternary ammonium compounds as potent antibacterials againstBiomolecules & biomedicine · 2026Article
- Discovery of potential antiviral compounds and accelerating the therapeutic discovery against monkeypox virus.Scientific reports · 2026Article
- Structure-Function Insights into Quinuclidine-3-One BisQACs: Synthesis, Modulation of Bacterial Resistance, Structure-Activity Relationship, and Biological Profiling.Pharmaceuticals (Basel, Switzerland) · 2025Article
- TargetingFrontiers in bioinformatics · 2025Article
- Article
- Repurposing FIASMAs against Acid Sphingomyelinase for COVID-19: A Computational Molecular Docking and Dynamic Simulation Approach.Molecules (Basel, Switzerland) · 2023Article
- Prediction of DNA-Binding Protein-Drug-Binding Sites Using Residue Interaction Networks and Sequence Feature.Frontiers in bioengineering and biotechnology · 2022Article
- Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections.Viruses · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fundamental aim of drug design in research and development is to invent molecules with selective affinity towards desired disease-associated targets. At the atomic loci of binding surfaces, systematic structural variations can define affinities between drug candidates and biomolecules, and thereby guide the optimization of safety, efficacy and pharmacologic properties. Hydrophobic interaction between biomolecules and drugs is integral to binding affinity and specificity. Examples of antiviral drug discovery are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.